Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CHMA

Chiasma (CHMA) Stock Price, News & Analysis

Chiasma logo

About Chiasma Stock (NASDAQ:CHMA)

Advanced Chart

Key Stats

Today's Range
$3.76
$3.76
50-Day Range
$3.76
$4.71
52-Week Range
$2.77
$5.74
Volume
147 shs
Average Volume
2.12 million shs
Market Capitalization
$217.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Receive CHMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chiasma and its competitors with MarketBeat's FREE daily newsletter.

CHMA Stock News Headlines

Chiasma Craters on FDA Drug Rejection
Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
MPM ASSET MANAGEMENT LLC Buys - GuruFocus.com
See More Headlines

CHMA Stock Analysis - Frequently Asked Questions

Chiasma, Inc. (NASDAQ:CHMA) issued its earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.18. The biotechnology company earned $1.92 million during the quarter, compared to the consensus estimate of $1.80 million.

Chiasma (CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), Meta Platforms (META), GW Pharmaceuticals (GWPH), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
5/06/2021
Today
5/01/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CHMA
Fax
N/A
Employees
85
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-74,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.11 million
Price / Cash Flow
N/A
Book Value
$1.59 per share
Price / Book
2.36

Miscellaneous

Free Float
N/A
Market Cap
$217.68 million
Optionable
Not Optionable
Beta
1.28

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CHMA) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners